Comparative Pharmacology
Head-to-head clinical analysis: LIORESAL versus PARAFLEX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LIORESAL versus PARAFLEX.
LIORESAL vs PARAFLEX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
GABA-B receptor agonist; inhibits monosynaptic and polysynaptic reflexes at the spinal cord level by reducing excitatory neurotransmitter release.
Centrally acting muscle relaxant; inhibits polysynaptic reflexes at the spinal cord level, possibly by depressing the central nervous system.
Oral: Initial 5 mg 3 times daily, increase by 5 mg per dose every 3 days to a maximum of 80 mg/day (20 mg 4 times daily). Intrathecal: Test dose 50-100 mcg; maintenance infusion 300-800 mcg/day.
250-500 mg orally once daily, may increase to 500 mg twice daily if needed. Maximum 500 mg/day.
None Documented
None Documented
Terminal elimination half-life: 2.5-4 hours. Clinically, accumulation occurs in renal impairment, requiring dose adjustment.
Terminal elimination half-life is approximately 2–3 hours, allowing for multiple daily dosing.
Renal: approximately 70-80% of the dose as unchanged drug and metabolites (primarily glucuronide conjugate); minor biliary/fecal elimination (<5%).
Renal excretion of unchanged drug and metabolites accounts for approximately 50% of an oral dose; fecal excretion accounts for about 20%.
Category C
Category C
Skeletal Muscle Relaxant
Skeletal Muscle Relaxant